FindTrial
Sign In

Real world study of how well Abemaciclib and Ribociclib work after routine treatment in hormone positive breast cancer patients

Clinical outcomes of Adjuvant CDK4/6 inhibitors in HR positive breast cancer- real word data from India. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/097599
Enrollment
150
Registered
2025-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 8- Other Procedures

Interventions

Intervention1: Nil: Nil

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Hormone positive breast cancer who received treatment with Abemaciclib or Ribociclib at TMH or ACTREC Mumbai

Exclusion criteria

Exclusion criteria: Patients who have not received any treatment at TMH, Parel.

Design outcomes

Primary

MeasureTime frame
Toxicities and completion ratesTimepoint: Baseline and after treatment completion—

Secondary

MeasureTime frame
Invasive disease -free survival Acute & early late toxicities from loco-regional radiationTimepoint: Basline & after treatment completion—

Countries

India

Contacts

Public ContactDr Sushmita Rath

Tata Memorial Hospital

sushmitarath73@gmail.com09869154396

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026